Ferratum Oyj
Ferratum Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Frederik Strange
Position: Member of the Board/Deputy member
Issuer: Ferratum Oyj
LEI: 74370078YLPFWHE33716
Notification type: INITIAL NOTIFICATION
Reference number: 74370078YLPFWHE33716_20210115190601_10
____________________________________________
Transaction date: 2021-01-15
Venue: XETRA - REGULIERTER MARKT (XETA)
Instrument type: SHARE
ISIN: FI4000106299
Nature of the transaction: ACQUISITION
Transaction details
(1): Volume: 2,350 Unit price: 5.8 EUR
Aggregated transactions
(1): Volume: 2,350 Volume weighted average price: 5.8 EUR
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S7.12.2025 13:50:00 CET | Press release
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
SALI7.12.2025 02:14:21 CET | Press release
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
Evaxion6.12.2025 20:00:00 CET | Press release
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Genmab A/S6.12.2025 15:30:00 CET | Press release
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Io Therapeutics, Inc.6.12.2025 14:05:00 CET | Press release
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom